Pharmacogenomic Markers of Glucocorticoid Response in The Initial Phase of Remission Induction Therapy in Childhood Acute Lymphoblastic Leukemia

BACKGROUND: Response to glucocorticoid (GC) monotherapy in the initial phase of remission induction treatment in childhood acute lymphoblastic leukemia (ALL) represents important biomarker of prognosis and outcome. We aimed to study variants in several pharmacogenes (NR3C1, GSTs and ABCB1) that coul...

Descripción completa

Detalles Bibliográficos
Autores principales: Gasic, Vladimir, Zukic, Branka, Stankovic, Biljana, Janic, Dragana, Dokmanovic, Lidija, Lazic, Jelena, Krstovski, Nada, Dolzan, Vita, Jazbec, Janez, Pavlovic, Sonja, Kotur, Nikola
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Sciendo 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6137363/
https://www.ncbi.nlm.nih.gov/pubmed/30210047
http://dx.doi.org/10.2478/raon-2018-0034

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6137363/
https://www.ncbi.nlm.nih.gov/pubmed/30210047
http://dx.doi.org/10.2478/raon-2018-0034

Ejemplares similares